Orchard Therapeutics plc (ORTX)
Jan 24, 2024 - ORTX was delisted (reason: acquired by Kyowa Kirin)
16.70
0.00 (0.00%)
Last trade price

Orchard Therapeutics Statistics

Total Valuation

ORTX has a market cap or net worth of $756.82 million. The enterprise value is $679.23 million.

Market Cap 756.82M
Enterprise Value 679.23M

Important Dates

The last earnings date was Monday, March 4, 2024, before market open.

Earnings Date Mar 4, 2024
Ex-Dividend Date n/a

Share Statistics

ORTX has 45.32 million shares outstanding.

Shares Outstanding 45.32M
Owned by Insiders (%) 12.21%
Owned by Institutions (%) 103.60%
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 34.65
Forward PS 15.26
PB Ratio 9.43
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 31.10
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.12, with a Debt / Equity ratio of 0.60.

Current Ratio 3.12
Quick Ratio 2.67
Debt / Equity 0.60
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -18.24

Financial Efficiency

Return on equity (ROE) is -74.90% and return on invested capital (ROIC) is -79.65%.

Return on Equity (ROE) -74.90%
Return on Assets (ROA) -33.50%
Return on Capital (ROIC) -79.65%
Revenue Per Employee $131,560
Profits Per Employee -$439,283
Employee Count 166
Asset Turnover 0.10
Inventory Turnover n/a

Taxes

Income Tax -140,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +173.77% in the last 52 weeks. The beta is 0.55, so ORTX's price volatility has been lower than the market average.

Beta (1Y) 0.55
52-Week Price Change +173.77%
50-Day Moving Average 16.33
200-Day Moving Average 9.46
Relative Strength Index (RSI) 85.36
Average Volume (30 Days) 107,408

Short Selling Information

Short Interest 27,197
Short Previous Month 41,001
Short % of Shares Out 0.15%
Short % of Float n/a
Short Ratio (days to cover) 0.28

Income Statement

In the last 12 months, ORTX had revenue of $21.84 million and -$72.92 million in losses. Loss per share was -$4.00.

Revenue 21.84M
Gross Profit 15.11M
Operating Income -102.02M
Pretax Income -73.06M
Net Income -72.92M
EBITDA -66.59M
EBIT -69.26M
Loss Per Share -$4.00
Full Income Statement

Balance Sheet

The company has $125.41 million in cash and $47.82 million in debt, giving a net cash position of $77.59 million or $1.71 per share.

Cash & Cash Equivalents 125.41M
Total Debt 47.82M
Net Cash 77.59M
Net Cash Per Share $1.71
Equity / Book Value 80.26M
Book Value Per Share 1.77
Working Capital 104.55M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$93.32 million and capital expenditures $6.87 million, giving a free cash flow of -$86.44 million.

Operating Cash Flow -93.32M
Capital Expenditures 6.87M
Free Cash Flow -86.44M
FCF Per Share -$3.79
Full Cash Flow Statement

Margins

Gross margin is 69.17%, with operating and profit margins of -467.13% and -333.90%.

Gross Margin 69.17%
Operating Margin -467.13%
Pretax Margin -334.54%
Profit Margin -333.90%
EBITDA Margin -304.93%
EBIT Margin -317.16%
FCF Margin -395.82%

Dividends & Yields

ORTX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -78.24%
Shareholder Yield -78.24%
Earnings Yield -9.64%
FCF Yield -11.42%

Analyst Forecast

The average price target for ORTX is $21.67, which is 29.76% higher than the current price. The consensus rating is "Buy".

Price Target $21.67
Price Target Difference 29.76%
Analyst Consensus Buy
Analyst Count 3
Revenue Growth Forecast (5Y) 31.76%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on March 10, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date Mar 10, 2023
Split Type Reverse
Split Ratio 1:10

Scores

ORTX has an Altman Z-Score of -3.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -3.37
Piotroski F-Score 2